ConductScience.org, home

Paper1968449

The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells.

Fujiwara M and 3 others. Immunopharmacology, 1990. Cited by 16 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. Papers, record 1968449. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1968449

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells.
PubMed
Journal
Immunopharmacology
PubMed
Year
1990
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
0.7
iCite
Revised in PubMed
2019-09-18
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fujiwara MM
2Mitsui KK
3Ishida JJ
4Yamamoto II

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibody FormationMajor topic
Immunosuppressive AgentsMajor topic
SpleenMajor topic
SulfasalazineMajor topic
Animals
Erythrocytes
In Vitro Techniques
Interleukin-2
Kinetics
Mice
Mice, Inbred BALB C
Mice, Inbred DBA
Sheep
T-Lymphocytes

Source PubMed

Download CSV of topics

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
31810227Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents.J Clin Med2019https://conductscience.org/library/papers/31810227PubMed
24723200Pediatric ulcerative colitis: a practical guide to management.Paediatr Drugs2014https://conductscience.org/library/papers/24723200PubMed
16984937Sulphasalazine inhibits human antigen-specific immune responses in vivo.Ann Rheum Dis2007https://conductscience.org/library/papers/16984937PubMed
8097101Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.Br J Clin Pharmacol1993https://conductscience.org/library/papers/8097101PubMed
7843946Crohn's disease and multiple sclerosis: a single case report.Ital J Neurol Sci1994https://conductscience.org/library/papers/7843946PubMed
1350243Sulfasalazine. Multiplicity of action.Dig Dis Sci1992https://conductscience.org/library/papers/1350243PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1968449

GET https://conductscience.org/api/papers/v1/1968449/authors